Published in Springerplus on February 03, 2015
Serum creatine kinase isoenzymes in children with osteogenesis imperfecta. Osteoporos Int (2016) 0.78
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med (2009) 4.39
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Osteoclasts: what do they do and how do they do it? Am J Pathol (2007) 2.93
The comparative enzymology of creatine kinases. I. Isolation and characterization from chicken and rabbit tissues. J Biol Chem (1967) 2.54
New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des (2003) 2.44
Endosome acidification and receptor trafficking: bafilomycin A1 slows receptor externalization by a mechanism involving the receptor's internalization motif. Mol Biol Cell (1993) 2.09
The relationship between the chemistry and biological activity of the bisphosphonates. Bone (2011) 1.86
Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. J Biol Chem (2012) 1.66
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int (2008) 1.42
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone (2001) 1.32
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem (2001) 1.22
Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption. Nat Med (2008) 1.16
P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J (2011) 1.07
Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab (2002) 1.04
Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem (2011) 1.03
Creatine kinase-mediated ATP supply fuels actin-based events in phagocytosis. PLoS Biol (2008) 0.98
Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum (2011) 0.97
Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab (2004) 0.97
Tissue- and cell-specific distribution of creatine kinase B: a new and highly specific monoclonal antibody for use in immunohistochemistry. Cell Tissue Res (1995) 0.96
The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors. Bone (2012) 0.94
Purinergic signalling in the musculoskeletal system. Purinergic Signal (2013) 0.93
Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone (1999) 0.90
Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res (1996) 0.89
RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis. J Biol Chem (2010) 0.87
Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int (1998) 0.83
Osteoclast molecular phenotyping by random cDNA sequencing. Bone (1995) 0.82
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway. Biochem Pharmacol (2012) 0.82
ATP-induced osteoclast function: the formation of sealing-zone like structure and the secretion of lytic granules via microtubule-deacetylation under the control of Syk. Genes Cells (2009) 0.80
Elevated levels of creatine kinase BB isoenzyme in three patients with adult osteopetrosis. N Engl J Med (1989) 0.79
Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull (2003) 0.78
Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts. Bone (2003) 0.77